Gastric MALT Lymphoma: Old and New Insights

Overview

Journal Ann Gastroenterol

Specialty Gastroenterology

Date 2014 Apr 10

PMID 24714739

Citations 48

Authors

Angelo Zullo

Cesare Hassan

Lorenzo Ridola

Alessandro Repici

Raffaele Manta

Alessandro Andriani

Affiliations

Soon will be listed here.

Abstract

The stomach is the most frequent site of extranodal lymphoma. Gastric lymphoma originating from mucosa-associated lymphoid tissue (MALT) is typically a low-grade, B-cell neoplasia strongly associated with () infection. Only certain strains in some predisposed patients determine lymphoma development in the stomach, according to a strain-host-organ specific process. The clinical presentation is poorly specific, symptoms ranging from vague dyspepsia to alarm symptoms. Similarly, different endoscopy patterns have been described for gastric lymphoma. eradication is advised as first-line therapy in early stage disease, and complete lymphoma remission is achieved in 75% of cases. Neoplasia stage, depth of infiltration in the gastric wall, presence of the translocation, localization in the stomach, and patient ethnicity have been identified as predictors of remission. Recent data suggests that eradication therapy may be successful for gastric lymphoma treatment also in a small subgroup (15%) of -negative patients. The overall 5-year survival and disease-free survival rates are as high as 90% and 75%, respectively. Management of patients who failed to achieve lymphoma remission following eradication include radiotherapy, chemotherapy and, in selected cases, surgery.

Citing Articles

Role of high-dose amoxicillin dual therapy for eradication in an Irish cohort: A prospective study.

Palmirotta R, Cafiero C, Colella M World J Clin Cases. 2024; 12(35):6859-6863.

PMID: 39687639 PMC: 11525908. DOI: 10.12998/wjcc.v12.i35.6859.

Simultaneous Presentation of Gastric and Orbital Mucosa-Associated Lymphoid Tissue Lymphoma: A Case Report.

Mirzaee E, Garousi M, Jafari S, Soltani S, Rakhshani N, Abdi N Clin Case Rep. 2024; 12(12):e9712.

PMID: 39664740 PMC: 11631787. DOI: 10.1002/ccr3.9712.

: High dose amoxicillin does not improve primary or secondary eradication rates in an Irish cohort.

Costigan C, OSullivan A, OConnell J, Sengupta S, Butler T, Molloy S World J Clin Cases. 2024; 12(16):2773-2779.

PMID: 38899284 PMC: 11185322. DOI: 10.12998/wjcc.v12.i16.2773.

Definitive Radiotherapy for Stage I Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Cohort of Unique-Dose Administration of 30 Gy in 15 Fractions and Analysis of Remission Duration.

Katano A, Yamashita H World J Oncol. 2024; 15(3):506-510.

PMID: 38751706 PMC: 11092405. DOI: 10.14740/wjon1846.

Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for ?.

Laoruangroj C, Habermann T, Wang Y, King R, Lester S, Thompson C JCO Oncol Pract. 2024; 20(8):1103-1108.

PMID: 38713887 PMC: 11368162. DOI: 10.1200/OP.23.00624.

References

Fischbach W, Goebeler M, Ruskone-Fourmestraux A, Wundisch T, Neubauer A, Raderer M . Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut. 2007; 56(12):1685-7. PMC: 2095715. DOI: 10.1136/gut.2006.096420. View

Psyrri A, Papageorgiou S, Economopoulos T . Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008; 19(12):1992-9. PMC: 2733120. DOI: 10.1093/annonc/mdn525. View

Abe S, Oda I, Inaba K, Suzuki H, Yoshinaga S, Nonaka S . A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Jpn J Clin Oncol. 2013; 43(9):917-22. DOI: 10.1093/jjco/hyt097. View

Planelles L, Medema J, Hahne M, Hardenberg G . The expanding role of APRIL in cancer and immunity. Curr Mol Med. 2008; 8(8):829-44. DOI: 10.2174/156652408786733711. View

Genta R, Hamner H, Graham D . Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol. 1993; 24(6):577-83. DOI: 10.1016/0046-8177(93)90235-9. View

Zullo A, Hassan C, Andriani A, Cristofari F, Cardinale V, Spinelli G . Primary low-grade and high-grade gastric MALT-lymphoma presentation. J Clin Gastroenterol. 2009; 44(5):340-4. DOI: 10.1097/MCG.0b013e3181b4b1ab. View

Isaacson P, Du M . MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004; 4(8):644-53. DOI: 10.1038/nrc1409. View

Malfertheiner P, Megraud F, OMorain C, Atherton J, Axon A, Bazzoli F . Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5):646-64. DOI: 10.1136/gutjnl-2012-302084. View

Miehlke S, Meining A, Morgner A, Bayerdorffer E, Lehn N, Stolte M . Frequency of vacA genotypes and cytotoxin activity in Helicobacter pylori associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Clin Microbiol. 1998; 36(8):2369-70. PMC: 105053. DOI: 10.1128/JCM.36.8.2369-2370.1998. View

10.

Zucca E, Roggero E, Bertoni F, Cavalli F . Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997; 8(8):727-37. DOI: 10.1023/a:1008282818705. View

11.

Beal K, Yeung H, Yahalom J . FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005; 16(3):473-80. DOI: 10.1093/annonc/mdi093. View

12.

Munari F, Lonardi S, Cassatella M, Doglioni C, Cangi M, Amedei A . Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood. 2011; 117(24):6612-6. DOI: 10.1182/blood-2010-06-293266. View

13.

Bertoni F, Zucca E . Delving deeper into MALT lymphoma biology. J Clin Invest. 2006; 116(1):22-6. PMC: 1323273. DOI: 10.1172/JCI27476. View

14.

Nakamura M, Takahashi T, Matsui H, Takahashi S, Murayama S, Suzuki H . New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib. Curr Pharm Des. 2013; 20(7):1097-103. PMC: 4260359. DOI: 10.2174/13816128113199990420. View

15.

De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C . Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; 19(4):409-14. View

16.

Park S, Jung H, Kim D, Kim M, Lee J, Choi K . Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori. Gut Liver. 2012; 6(2):270-4. PMC: 3343168. DOI: 10.5009/gnl.2012.6.2.270. View

17.

Lin W, Tsai H, Kuo S, Wu M, Lin C, Hsu P . Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res. 2010; 70(14):5740-8. DOI: 10.1158/0008-5472.CAN-09-4690. View

18.

Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E . Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009; 104(8):1932-7. DOI: 10.1038/ajg.2009.314. View

19.

Kawahara Y, Mizuno M, Yoshino T, Yokota K, Oguma K, Okada H . HLA-DQA1*0103-DQB1*0601 haplotype and Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2005; 3(9):865-8. DOI: 10.1016/s1542-3565(05)00185-0. View

20.

Raderer M, Streubel B, Wohrer S, Hafner M, Chott A . Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2005; 55(5):616-8. PMC: 1856121. DOI: 10.1136/gut.2005.083022. View